About us

About NanoMed Targeting Systems (NTS).

NanoMed Targeting Systems (NTS) is an early stage company founded in Oklahoma City, OK in 2010. NTS’s mission and focus is to develop, manufacture and market magnetically targeted drug delivery systems. The platform system is based on proprietary magnetic nanoformulations attached to therapeutic payload(s), and its non-invasive proprietary magnetic guiding system. NTS is currently working on Targeting System to treat Atrial Fibrillation, the most common cardiac arrhythmia.

NTS is a joint research between Oklahoma University Health Sciences Center (OUHSC) and BBMS Ltd., an Israeli startup company (“the Parties”). NTS conducted successful initial animal trials of Autonomic Denervation with Magnetic Nanoparticles that demonstrated applicability of targeted nanomagnetic particles for treatment of atrial fibrillation (Circulation 2010, 122:2653-2659).

NanoMed System

Prescription Fulfillment
Diagram showing nanoparticle/DNA complexes added to cells in culture with a magnet applied underneath.
Health Screenings